---
title: "Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer"
id: "nejm-11-trastuzumab-deruxtecan-in-residual-her2-positive-early-breast-cancer"
canonical_url: "https://medichelpline.com/clinical-feed/nejm-11-trastuzumab-deruxtecan-in-residual-her2-positive-early-breast-cancer"
content_type: "clinical_feed_article"
specialty: "Research Highlights"
source_name: "New England Journal of Medicine"
source_url: "https://www.nejm.org/doi/full/10.1056/NEJMx260006?af=R&rss=currentIssue"
published_at: "2026-04-01T09:00:03.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/nejm-11-trastuzumab-deruxtecan-in-residual-her2-positive-early-breast-cancer
- **Specialty:** [Research Highlights](https://medichelpline.com/clinical-feed/research-highlights.md)
- **Primary Source:** New England Journal of Medicine
- **Source URL:** [Original Journal Publication](https://www.nejm.org/doi/full/10.1056/NEJMx260006?af=R&rss=currentIssue)
- **Published At:** 2026-04-01T09:00:03.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
New England Journal of Medicine published a clinical update in Research Highlights on 01 Apr 2026. The item focuses on Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer. Review the original article for the full source wording and details.
## Clinical Analysis & Structured Key Points
New England Journal of Medicine published a clinical update in Research Highlights on 01 Apr 2026. The item focuses on Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer. Review the original article for the full source wording and details.
## Related Clinical Research

- [VISTA: Virtual spatial transcriptomics from H&E for prognostic and therapy response prediction in](https://medichelpline.com/clinical-feed/biorxiv-21-virtual-spatial-transcriptomics-from-histopathology-enables-prognostic-and.md)
- [Chemotherapy-Associated Colitis After TCbHP in HER2-Positive Breast Cancer: Case Report](https://medichelpline.com/clinical-feed/pubmed-42571049.md) (DOI: 10.12659/AJCR.952507)
- [Next-generation Antibody–Drug Conjugates: Strategies to Improve Efficacy and Clinical Development](https://medichelpline.com/clinical-feed/nature-0-the-next-generation-of-antibody-drug-conjugates.md)
- [Sympathetic Overdrive, Vascular Dysfunction, and Exercise Intolerance in Long-Term Breast Cancer](https://medichelpline.com/clinical-feed/journal-of-the-american-heart-association-65-sympathetic-neural-overactivation-vascular-dysfunction-and-exercise-intolerance-in-long-term-survivors-of-breast-cancer-treated-with-doxorubicin-and-trastuzumab-based-chemotherapy.md)
- [Neoadjuvant Taxane Plus Trastuzumab and Pertuzumab With or Without Carboplatin in HER2-Positive](https://medichelpline.com/clinical-feed/journal-of-clinical-oncology-23-neoadjuvant-taxane-plus-trastuzumab-and-pertuzumab-with-or-without-carboplatin-in-human-epidermal-growth-factor-receptor-2-positive-breast-cancer-the-randomized-noninferiority-phase-iii-neocarhp-trial.md)

## Navigation
- [← Back to Research Highlights Feed](https://medichelpline.com/clinical-feed/research-highlights.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.